TrialPath
Recruiting

A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy

NCT07823322 · Incyte Corporation
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2 Study of INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy (NEXERA-204)
About this study
The purpose of this study is to evaluate INCA33890 in the treatment of circulating tumor DNA-positive stage II/III microsatellite stable colorectal cancer after curative resection and chemotherapy.
Eligibility criteria
Inclusion Criteria: * Received curative-intent (R0) resection of histologically confirmed Stage II or III colorectal adenocarcinoma. * Completed all neoadjuvant and/or adjuvant chemotherapy, including at least 3 months of fluoropyrimidine-based chemotherapy. * Has minimal residual disease (MRD), defined as ctDNA positive by the Signatera™ assay (whole exome sequencing \[WES\] or whole genome sequencing \[WGS\]) in a blood sample collected between: * 2 weeks and 12 months after completion of adjuvant chemotherapy or * 4 weeks and 12 months after curative resection following total neoadjuvant therapy. Note: If the participant received any investigational therapy for MRD, ctDNA positivity must be confirmed in a blood sample collected at least 4 weeks after completion of that investigational therapy and within the applicable 12-month window described above. * Has no clinical or radiographic evidence of disease confirmed by chest, abdominal, and pelvic PET-CT scan and by brain imaging (MRI or CT scan with contrast) within 4 weeks prior to C1D1 study drug administration. * ECOG performance status of 0 or 1. * Adequate organ function determined by laboratory results. Exclusion Criteria: * History of metastatic (Stage IV) colorectal adenocarcinoma, including oligometastatic disease or metastatic recurrence, even if all metastatic sites and the primary tumor were completely resected and the patient is currently without evidence of disease. * MSI-H/dMMR per historical data in the medical record. * History of other malignancy within 2 years. * Treatment with an anti-PD-(L)1 or anti-CTLA-4 for any indication within the last 3 years. * Active autoimmune disease that has required systemic treatment in the past 2 years. * Significant concurrent and/or uncontrolled medical condition. * History of organ transplant, including allogeneic stem cell transplantation. Other protocol-defined inclusion/exclusion criteria apply.
Study design
Enrollment target: 40 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-12-14
Estimated completion: 2029-05-14
Last updated: 2026-11-17
Interventions
Drug: INCA33890
Primary outcomes
  • • Circulating tumor DNA (ctDNA) clearance (3 months)
Sponsor
Incyte Corporation · industry
Contacts & investigators
ContactIncyte Corporation Call Center (US) · contact · medinfo@incyte.com · 1.855.463.3463
ContactIncyte Corporation Call Center (ex-US) · contact · eumedinfo@incyte.com · +800 00027423
InvestigatorIncyte Medical Monitor · study_director, Incyte Corporation
All locations (15)
City of Hope Medical CenterNot Yet Recruiting
Duarte, California, United States
Oncura HealthNot Yet Recruiting
Glendale, California, United States
City of Hope Medical CenterNot Yet Recruiting
Irvine, California, United States
City of Hope - Chicago Cancer CenterNot Yet Recruiting
Zion, Illinois, United States
Maryland Oncology Hematology P.A.Not Yet Recruiting
Rockville, Maryland, United States
The University of North Carolina At Chapel HillNot Yet Recruiting
Chapel Hill, North Carolina, United States
University of Pittsburgh Medical CenterNot Yet Recruiting
Pittsburgh, Pennsylvania, United States
Tennessee Oncology, PllcNot Yet Recruiting
Nashville, Tennessee, United States
Vanderbilt University Medical CenterNot Yet Recruiting
Nashville, Tennessee, United States
Texas Oncology Northeast LocationNot Yet Recruiting
Flower Mound, Texas, United States
Md Anderson Cancer CenterNot Yet Recruiting
Houston, Texas, United States
Texas OncologyNot Yet Recruiting
Webster, Texas, United States
Virginia Cancer Specialists, PcNot Yet Recruiting
Fairfax, Virginia, United States
Fred Hutchinson Cancer CenterNot Yet Recruiting
Seattle, Washington, United States
Pan American Center For Oncology Trials, LlcRecruiting
Ponce, Puerto Rico